Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome.

Literature DB >> 17891446

Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome.

Yasuyo Kashiwagi¹, Hisashi Kawashima, Shigeo Nishimata, Ryuhei Nagao, Kiyoko Watanabe, Kouji Takekuma, Akinori Hoshika.

Abstract

We describe a case of severe CINCA syndrome in a Japanese male infant. We recently managed with anti-interleukin 1 agent (anakinra). Anakinra immediately led to improvement of both the clinical symptoms and the laboratory findings.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2007 PMID： 17891446 DOI： 10.1007/s10067-007-0734-7

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

14 in total

1. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome.

Authors: B Granel; J Serratrice; P Disdier; P-J Weiller
Journal: Rheumatology (Oxford) Date: 2005-01-25 Impact factor: 7.580

2. Anakinra in mutation-negative CINCA syndrome.

Authors: José Luis Callejas; Javier Oliver; Javier Martín; Norberto Ortego
Journal: Clin Rheumatol Date: 2006-01-27 Impact factor: 2.980

3. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.

Authors: Daniel J Lovell; Suzanne L Bowyer; Alan M Solinger
Journal: Arthritis Rheum Date: 2005-04

4. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.

Authors: Ivona Aksentijevich; Miroslawa Nowak; Mustapha Mallah; Jae Jin Chae; Wendy T Watford; Sigrun R Hofmann; Leonard Stein; Ricardo Russo; Donald Goldsmith; Peter Dent; Helene F Rosenberg; Frances Austin; Elaine F Remmers; James E Balow; Sergio Rosenzweig; Hirsh Komarow; Nitza G Shoham; Geryl Wood; Janet Jones; Nadira Mangra; Hector Carrero; Barbara S Adams; Terry L Moore; Kenneth Schikler; Hal Hoffman; Daniel J Lovell; Robert Lipnick; Karyl Barron; John J O'Shea; Daniel L Kastner; Raphaela Goldbach-Mansky
Journal: Arthritis Rheum Date: 2002-12

5. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors: C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal: Nature Date: 1990-01-25 Impact factor: 49.962

6. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes.

Authors: Jérôme Feldmann; Anne-Marie Prieur; Pierre Quartier; Patrick Berquin; Stephanie Certain; Elisabetta Cortis; Dominique Teillac-Hamel; Alain Fischer; Genevieve de Saint Basile
Journal: Am J Hum Genet Date: 2002-05-24 Impact factor: 11.025

7. Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel.

Authors: Joost Frenkel; Nico M Wulffraat; Wietse Kuis
Journal: Arthritis Rheum Date: 2004-11

8. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene.

Authors: Tadashi Matsubayashi; Hiroshi Sugiura; Takashi Arai; Tsutomu Oh-Ishi; Yasuji Inamo
Journal: Acta Paediatr Date: 2006-02 Impact factor: 2.299

9. A case report of neonatal onset multisystemic inflammatory disease in Japan treated with continuous hemodiafiltration and steroid pulse therapy.

Authors: Hisashi Kawashima; Akiko Sato; Shigeo Nishimata; Naoto Yamada; Yasuyo Kashiwagi; Kiyoko Watanabe; Kouji Takekuma; Akinori Hoshika; Takurou Ozawa
Journal: Ther Apher Dial Date: 2007-06 Impact factor: 1.762